Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Jin G ChoiRyan D NippAngela TramontanoAyman AliTiannan ZhanPari PandharipandeEmily C DowlingCristina R FerroneTheodore S HongDeborah SchragCarlos Fernandez-Del CastilloDavid P RyanChung Yin KongChin HurPublished in: The oncologist (2018)
Increasingly, neoadjuvant FOLFIRINOX has been used for borderline resectable and locally advanced pancreatic cancer with the goal of rendering them resectable and decreasing risk of recurrence. Despite many efforts to show the benefits of neoadjuvant over adjuvant therapies, clinical evidence to guide this decision is largely lacking. Decision-analytic modeling can provide a methodologic platform that integrates the best available data to quantitatively explore clinical decisions by simulating a hypothetical clinical trial. This modeling analysis suggests that neoadjuvant FOLFIRINOX is preferable to upfront surgery and adjuvant therapies by various outcome metrics including quality-adjusted life years, overall survival, and incremental cost-effectiveness ratio.
Keyphrases
- locally advanced
- rectal cancer
- neoadjuvant chemotherapy
- squamous cell carcinoma
- phase ii study
- radiation therapy
- clinical trial
- early stage
- minimally invasive
- randomized controlled trial
- machine learning
- high throughput
- big data
- lymph node
- deep learning
- atrial fibrillation
- phase ii
- double blind
- surgical site infection